Clinical Trials

518 enrolled

Urinary Bladder Neoplasms

NCT05285358 2026-06-05

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Phase 1 Suspended

12 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06211764 2026-06-05

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-06-05

MoonRISe-1

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-06-05

MoonRISe-3

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07007559 2026-06-05

ASPEN-09-03

120 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03816163 2026-06-04

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

393 enrolled

Pancreatic Neoplasms

NCT04984837 2026-06-04

Study of Lacutamab in Peripheral T-cell Lymphoma

49 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05139017 2026-06-04

waveLINE-003

Phase 2/3 Recruiting

290 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

60 enrolled

Phase 2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07021989 2026-06-04

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Phase 1 Not yet recruiting

Hodgkin Disease

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms, Cholangiocarcinoma

NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04267848 2026-06-03

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

131 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04753879 2026-06-03

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

38 enrolled

Pancreatic Neoplasms

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

88 enrolled

Liver Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06624085 2026-06-03

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

50 enrolled

Lymphoma

NCT06770452 2026-06-03

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

133 enrolled

Pancreatic Neoplasms

NCT06770582 2026-06-03

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Phase 2/3 Active not recruiting

Urinary Bladder Neoplasms

NCT07076121 2026-06-03

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

470 enrolled

Pancreatic Neoplasms

NCT07483554 2026-06-03

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

389 enrolled

CLDN18.2 Positive

NCT07491445 2026-06-03

RASolute 303

900 enrolled

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Phase 3 Not yet recruiting

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07564141 2026-06-03

RAINFOL™-07

688 enrolled

Ovarian Neoplasms

NCT01585805 2026-06-02

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

83 enrolled 23 charts

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04104672 2026-06-02

ARC-8

Phase 1 Active not recruiting

196 enrolled

Phase 1/2 Active not recruiting

Pancreatic Neoplasms

NCT04542824 2026-06-02

EPCORE™ NHL-3

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-06-02

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06608927 2026-06-02

PRISM-1

610 enrolled

Pancreatic Neoplasms

NCT06619236 2026-06-02

RAINFOL-02

448 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06625320 2026-06-02

RASolute 302

500 enrolled

Pancreatic Neoplasms

NCT06632327 2026-06-02

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06917079 2026-06-02

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

665 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07000084 2026-06-02

GAIN-BCG

330 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07144254 2026-06-02

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Phase 1 Recruiting

24 enrolled

Sarcoma

Osteosarcoma

NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07604766 2026-06-02

RAINFOL-02

82 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07621718 2026-06-02

RASolute 305

670 enrolled

Pancreatic Neoplasms

NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT06360354 2026-06-01

MTAPESTRY 103

120 enrolled

Neoplasms, Pancreatic Neoplasms

NCT06788912 2026-06-01

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07036380 2026-06-01

TACTIC

75 enrolled

Advanced Biliary Tract Carcinoma

NCT07214779 2026-06-01

MAESTRA 2

466 enrolled

Phase 4 Not yet recruiting

Ovarian Neoplasms

NCT07619235 2026-06-01

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

32 enrolled